Brussels, 30/07/2012 (Agence Europe) - As announced by Commissioner Almunia last week (see EUROPE 10663) and following up on proceedings initiated in July 2009 (see EUROPE 9938), on Monday 30 July 2012, the European Commission sent a statement of objections to French pharmaceutical company Servier and other pharmaceutical companies about their practices delaying the sale of generic perindopril, a cardiovascular drug made by Servier. The Commission says the patent settlement agreements...